Status:
COMPLETED
Follow-up of Ph+ Chronic Myleoid Leukemia Patients in Complete Cytogenetic Response With Interferon Based Therapy
Lead Sponsor:
Università degli Studi di Brescia
Conditions:
Chronic Myeloid Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
Objectives This is an observational study aimed at updating the overall survival (OS), the progression free survival (PFS) to accelerated-blastic (AB) phase and the complete cytogenetic response (CCg...
Detailed Description
Study rational * IFN, either alone or in combination with AC, prolonged survival of Ph+ CML patients, in early chronic phase, mainly in those patients achieving the CCgR * CCgR became the surrogate m...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Age \> 18 years
- Ph+/BCR-ABL+ CML in CP
- Treatment with IFN alpha alone or in combination ( i.e HU, Ara-C, YNK01, ASCT ), either within or outside national Study Protocols.
- Complete cytogenetic response (CCgR) (0% Ph+ cells)
- Written informed consent prior to any study procedures being performed.
- Exclusion Criteria:
- Patients with Ph+ CML in accelerated/blastic phase (AP/BP)
- No treatment with Interferon-alpha
- No written informed consent prior to any study procedures being performed.
Exclusion
Key Trial Info
Start Date :
October 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
116 Patients enrolled
Trial Details
Trial ID
NCT01490853
Start Date
October 1 2009
End Date
December 1 2014
Last Update
November 13 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chair of hematology
Brescia, Italy, 25123